Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBI268 local injection for postoperative analgesia after hemorrhoidectomy (phase II)
ChiCTR2600120556Phase 2Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Mar 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GBI268 in postoperative pain (5 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Area under the curve of resting pain score within 72 hours after dosing (AUC0–72h). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
GBI268
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600120556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120556.